** Shares of Trevi Therapeutics TRVI.O down 3.6% in extended trading to $6.09 as co plans equity raise
** New Haven, Connecticut-based firm commences $100 mln stock offering
** Morgan Stanley. Leerink, Stifel and Cantor are jt bookrunners
** Before the bell on Mon, co announced positive topline results from Phase II trial of its therapy, Haduvio, for patients with a type of chronic cough, and said plans Phase III initiation in 2026
** With ~101.7 mln shares outstanding, co has about $680 market cap, per LSEG data
** TRVI closed down 3% at $6.32 on Mon, trimming YTD gain to 53%
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。